ArticleAntimicrobial agents and chemotherapy2006
Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 36 citations in OpenAlex.
- A Second-Generation Fungerp Analog, SCY-247, Shows PotentAntimicrobial agents and chemotherapy · 2021Article
- The Emergence of Rare ClinicalFrontiers in microbiology · 2019Article
- Spondylodiscitis Due to Aspergillus terreus in an Immunocompetent Host: Case Report and Literature Review.Mycopathologia · 2016Article
- Mechanisms of echinocandin antifungal drug resistance.Annals of the New York Academy of Sciences · 2015Review
- rPbPga1 from Paracoccidioides brasiliensis Activates Mast Cells and Macrophages via NFkB.PLoS neglected tropical diseases · 2015Article
- Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.Drugs · 2014Review
- Chitin synthases with a myosin motor-like domain control the resistance of Aspergillus fumigatus to echinocandins.Antimicrobial agents and chemotherapy · 2012Article
- Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections.Antimicrobial agents and chemotherapy · 2012Article
- Review
- Emericella quadrilineata as cause of invasive aspergillosis.Emerging infectious diseases · 2008Review
- Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.Antimicrobial agents and chemotherapy · 2008Article
- Resistance to echinocandin-class antifungal drugs.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2007Review
- Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.Antimicrobial agents and chemotherapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The echinocandin caspofungin is a potent inhibitor of the activity of 1,3-beta-D-glucan synthase from Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. In murine models of disseminated infection, caspofungin prolonged survival and reduced the kidney fungal burden. Caspofungin was at least as effective as amphotericin B against these filamentous fungi in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.